Interviews

Experts at Maui Derm 2026 discuss the meeting’s focus on in-depth clinical education, practical patient care pearls, and interdisciplinary networking.

Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges.

Obesity market overview for employers: data on GLP-1s for obesity, digital solutions, and benefit strategies to control costs and outcomes.

A European Respiratory Journal study shows pulmonary fibrosis affects sexual function and quality of life, calling for open clinician-patient conversations.

Margaret Krackeler, MD, discusses real-world data supporting the switch from ibrutinib to zanubrutinib for chronic lymphocytic leukemia.

Donna Culton, MD, University of North Carolina at Chapel Hill, outlines diagnosing autoimmune blistering diseases.

Adopting zanubrutinib for the treatment of chronic lymphocytic leukemia showed improved tolerability and persistence, enhancing patient safety and outcomes.

Philip Mease, MD, discusses the different treatment options now available for patients with psoriasis and psoriatic arthritis.

Nate C. Apathy, PhD, guest editor of AJMC's 15th Health IT special issue, calls for tools to be closely aligned with user needs.

Paul Nghiem, MD, PhD, discusses individualized therapies and the evolving role of AI in improving outcomes for actinic keratosis and related skin conditions.

Lawrence Eichenfield, MD, outlines a patient-centered approach to atopic dermatitis, assessing disease history, life impact, and prior therapy use.

Daniel Siegel, MD, discusses a loophole he looks out for in ICD-10 coding and billing.

James Song, MD, discusses best practices and strategies for managing patients with psoriasis in 2026.

The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple myeloma, explained Roberto Mina, MD.

A multistakeholder study explores how law enforcement presence in EDs affects survivors of violence and outlines trauma-informed, patient-centered policy solutions.

There is a shift happening in mental health care, with real-world data and holistic evaluations improving patient outcomes and reducing disparities.

A new study finds law enforcement presence in emergency departments may disrupt care. Lead author Prashasti Bhatnagar discusses policy and training solutions.

David Muhlestein, PhD, breaks down ghost rates, data gaps, and why stronger oversight is needed to make Transparency in Coverage files usable for patients.

Explore the evolving GLP-1 landscape with insights from industry experts, shaping future health strategies and plan designs for employers.

As the FY26 budget is being negotiated, Jennifer Snow, MPA, of NAMI, emphasizes that funds must be directed to programs as Congress intends.

NAMI's National Director of Government Relations and Policy, Jennifer Snow, MPA, explains how advocates rallied in support of mental health care.

Jose Guzman Garcia, PharmD, MHA, BCCCP, discusses key pharmacy initiatives at UC Davis Health.

Alongside physician collaboration, patient advocacy is essential to ensure clinical trials and public policy reflect patient-centered outcomes.

Most workers are unprepared to shop for individual plans under ICHRAs, highlighting gaps in decision tools, guidance, and consumer protections.

ICHRAs could either stabilize or destabilize ACA risk pools, with adoption patterns raising concerns about access, equity, and coverage for sicker workers.

Aleata Postell discusses CenterWell Pharmacy's partnership with Eli Lilly to dispense FDA-approved obesity management drugs.

Presenters shared their personal highlights of attending ASCO GI 2026.